Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Public ClinicalTrials.gov record NCT07504458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Study identification
- NCT ID
- NCT07504458
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 150 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 71 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 7, 2026
- Primary completion
- Feb 28, 2027
- Completion
- Nov 30, 2030
- Last update posted
- Sep 9, 2026
2026 – 2030
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Quetzal Site 16 | Birmingham | Alabama | 35233 | Recruiting |
| Quetzal Site 1 | Duarte | California | 91010 | Recruiting |
| Quetzal Site 7 | Los Angeles | California | 90033 | Recruiting |
| Quetzal Site 5 | Stanford | California | 94305 | Recruiting |
| Quetzal Site 13 | Augusta | Georgia | 30912 | Recruiting |
| Quetzal Site 18 | Lexington | Kentucky | 40536 | Recruiting |
| Quetzal Site 23 | Baltimore | Maryland | 21201 | Recruiting |
| Quetzal Site 22 | Ann Arbor | Michigan | 48109 | Recruiting |
| Quetzal Site 4 | Buffalo | New York | 14203 | Recruiting |
| Quetzal Site 2 | The Bronx | New York | 10467 | Recruiting |
| Quetzal Site 8 | Columbus | Ohio | 43210 | Recruiting |
| Quetzal Site 12 | Nashville | Tennessee | 37203 | Recruiting |
| Quetzal Site 6 | Houston | Texas | 77030 | Recruiting |
| Quetzal Site 3 | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07504458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 9, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07504458 live on ClinicalTrials.gov.